Samsung Biologics agreed to acquire Swiss CDMO PolyPeptide for about $1.8 billion in cash, signaling a push deeper into peptide ingredient manufacturing. The transaction would extend Samsung Biologics’ manufacturing footprint beyond biologics into a manufacturing category that supports peptide-based therapeutics and ingredients. The deal reflects growing interest from larger CDMOs in end-to-end modalities coverage, especially as customers broaden portfolios that can include both biologics and peptide drug substances. For PolyPeptide, the sale offers scale and access to Samsung Biologics’ development and commercial customer base. As announced, the acquisition is positioned as a strategic step for Samsung Biologics to build capabilities across more parts of the value chain, aligning with its broader push for advanced manufacturing services. Details on timing and regulatory approvals were not included in the provided excerpt, but the price magnitude suggests the companies are aiming to accelerate growth through capability expansion rather than incremental capacity adds.